Clinical Trial Update: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing alirocumab (Praluent) to ezetimibe in patients with hypercholesterolemia assessed efficacy and safety. The study results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-11-06